Calderasib

Calderasib
Clinical data
Other names	MK-1084
Identifiers
	IUPAC name (5P,17aM)-20-chloro-2-[(2S,5R)-2,5-dimethyl-4-(prop-2-enoyl)piperazin-1-yl]-14,17-difluoro-6-(propan-2-yl)-11,12-dihydro-4H-1,18-ethenopyrido[4,3-e]pyrimido[1,6-g][1,4,7,9]benzodioxadiazacyclododecin-4-one;
PubChem CID	156295589;
UNII	YQF4ART47C;
ChEMBL	ChEMBL4875422;
Chemical and physical data
Formula	C32H31ClF2N6O4
Molar mass	637.08 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES C[C@@H]1CN([C@H](CN1C(=O)C=C)C)C2=NC(=O)N3C4=C(C=CN=C4C(C)C)OCCOC5=C(C=CC(=C5C6=C(C=C2C3=N6)Cl)F)F;
	InChI InChI=InChI=1S/C32H31ClF2N6O4/c1-6-24(42)39-14-18(5)40(15-17(39)4)30-19-13-20(33)27-25-21(34)7-8-22(35)29(25)45-12-11-44-23-9-10-36-26(16(2)3)28(23)41(31(19)37-27)32(43)38-30/h6-10,13,16-18H,1,11-12,14-15H2,2-5H3/t17-,18+/m1/s1; Key:BBIVCWWQPMOKAC-MSOLQXFVSA-N;

Calderasib is an investigational new drug that is being developed by Merck Sharp & Dohme for the treatment of solid tumors. It targets tumors that express G12C mutated KRAS protein.^[1]^[2]^[3]

References

↑ "Calderasib". AdisInsight. Springer Nature Switzerland AG. Retrieved 3 July 2026.
↑ Ma X, Sloman DL, Duggal R, Anderson KD, Ballard JE, Bharathan I, et al. (July 2024). "Discovery of MK-1084: An Orally Bioavailable and Low-Dose KRASG12C Inhibitor". Journal of Medicinal Chemistry. 67 (13): 11024–11052. doi:10.1021/acs.jmedchem.4c00572. PMID 38924388.
↑ Remon J, La-Cava G, Borgeaud M, Saw SP, Hendriks LE, Ricciuti B (June 2026). "KRAS G12C-mutant non-small cell lung cancer: A practical guide for clinicians". Cancer Treatment Reviews. 147 103144. doi:10.1016/j.ctrv.2026.103144. PMID 42114275.
↑ "FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung Cancer (NSCLC)". Merck.com. Merck & Co., Inc. 2026-05-29.

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.